Blog

C. Jillian Tsai: Phase II Study of Pembrolizumab and Chemoradiation in Head and Neck Cancer

C. Jillian Tsai/X

May 30, 2025, 05:52

C. Jillian Tsai: Phase II Study of Pembrolizumab and Chemoradiation in Head and Neck Cancer

C. Jillian Tsai, Lead of Palliative Radiotherapy and Oligometastases Program (PROP) at Princess Margaret Cancer Centre, posted on X:

“Remarkable efforts to obtain on-treatment tissue to study TME.

CRT with sequential pembro *might* be more favorable than concurrent pembro.”

Ttile: Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer

Authors: Dan P. Zandberg, Lazar Vujanovic, David A. Clump, Brian P. Isett, Hong Wang, Gabriel Sica, Riyue Bao, Housayin Li, James Ohr, Heath D. Skinner, Raja R. Seethala, Simion I. Chiosea, Robert L. Ferris, Julie E. Bauman

Read The Full Article at Journal of Clinical Oncology.

C. Jillian Tsai: Phase II Study of Pembrolizumab and Chemoradiation in Head and Neck Cancer

More posts featuring Head and Neck Cancer.

Brian P. Isett C. Jillian Tsai cancer Dan P. Zandberg David A. Clump Gabriel Sica Heath D. Skinner Hong Wang Housayin Li James Ohr Julie E. Bauman Lazar Vujanovic OncoDaily Oncology Raja R. Seethala Riyue Bao Robert L. Ferris Simion I. Chiosea

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Top 10 Immunotherapy Fellowships and Grants to Watch in 2025

July Is Sarcoma Awareness Month: What You Need to Know

Pat Soon-Shiong: SARS-CoV-2 Infection Can Awaken Sleeping Cancer Cells

Cary Adams' Keynote Message at Parliament House in Canberra - UICC